New Delhi [India], Feb 9 : The pharma-cum-healthcare major, Morepen Laboratories Ltd., has reported a yet another growth-filled quarter by registering a 23 percent rise in its net sales in the third quarter (Q3) of fiscal 2016-17.
The net sales increased to Rs. 134.05 crore in Q3 FY 2016-17 compared to Rs. 108.72 crore in the corresponding quarter of the previous fiscal.
Sales from the domestic operations contributed majorly to the company's top-line by registering a growth of 43 percent at Rs.79.52 crore in Q3 FY 2016-17. Export sales, however, remained flat during the quarter at Rs. 54.53 crore, registering a marginal growth of three percent.
New Delhi [India], Nov 27 : Healthcare e-commerce portal Netmeds has announced acquiring of Delhi-based hyper-local delivery app for health and medical needs, named Pluss.
"This acquisition makes a lot of sense for us, since it allows us to scale quicker, and shorten the delivery interval and improve efficiencies in Tier I metros. This has become even more incumbent upon us, as demonetization and the move to a cashless economy combined with a robust digital mobile consumerism fuel our growth. Most importantly, we further strengthen the Netmeds talent pool with people who bring on board a rich understanding of the space and technology," said CEO Netmeds, Pradeep Dadha.
Mumbai [India], Nov.21 : Capturing the latest trends in health and nutrition, DuPont presents a wide range of probiotic strains and blends to help develop products that differentiate.
Customers will now have an opportunity to expedite innovative new products to market in over-the-counter (OTC) nutrition supplements and pharmaceutical product categories in South Asia.
End consumers will benefit from the well-researched strain portfolio of DuPont Danisco FloraFIT customizable probiotics and HOWARU premium probiotics that address:
Digestive Health: solutions to restore ideal balance of gastrointestinal microflora
Immune Health: helps maintain natural immune defenses and support general well-being
Women's Health: clinically-documented to help maintain vaginal health
On Thursday, a federal jury ordered Gilead Sciences Inc to pay $200 million to Merck & Co in damages for infringing two Merck patents linked to a profitable hepatitis C cure. Merck had demanded $2 billion but the damage awarded to the company is quite less. The same jury in San Jose, California, supported the validity of the patents, on Tuesday, which are at the heart of the dispute related to Gilead's main drugs Sovaldi and Harvoni. As a whole, both the medicines had over $20 billion in US sales last year and a year prior to that.
UK-based GW Pharmaceuticals recently announced success of its cannabis-derived drug in clinical trials. The company’s market value doubled overnight after it made an announcement that revealed success of cannabis-derived drug Epidiolex in reducing seizures in children with a rare form of epilepsy.
The study was first of four final-stage Phase III epilepsy trials, results of other trails are yet to come this year. The study involved 120-patients, who were given Epidiolex. The patients were found to have fair reduction in monthly convulsive seizures that was 39%, more when compared with 13% of reduction with placebo intake.
Charged with securities fraud and facing congressional inquiry, ex drug executive Martin Shkreli has replaced his legal team with Benjamin Brafman, the lawyer who was behind getting Sean ‘Diddy’ Combs set free of gun and bribery charges in 2001.
The move has been taken after Shkreli was lately called ‘the most hated man in America’ for the sky-high rates he set on life-saving medications, has boarded a risky strategy for repairing his image without any assistance of professional communications advisers.
Sanofi has come up with a project to create a vaccine against the Zika virus. The is the most decisive commitment so far by any leading vaccine producer to battle the disease associated with multiple birth defects in Brazil.
On Tuesday, the French drugmaker said that its Sanofi Pasteur vaccines division has decided to utilize its expertise in creating vaccines for similar viruses like yellow fever, Japanese encephalitis and, the dengue most recently.
The move has been taken a day after the World Health Organization (WHO) has declared the mosquito-borne Zika virus as an international public health emergency because of its association with underdeveloped brains in a number of babies.
The leukemia medicine Gleevec that is manufactured by Novartis now has a competitor. A generic variant of the medicine has been introduced by Sun Pharma on February 1, 2016, in the United States. Sun Pharma is likely to price the generic version around 30% less than the price of Gleevc, expecting to take over one-third market within the coming six-month period, according to Kal Sundaram, the Chief Executive Officer of Sun In North America.
Walgreens and Theranos had entered into a partnership just over two years ago to make the latter’s revolutionary blood test technology available to people through the pharmacies of Walgreens across the nation. However, the partnership seems to be suffering a setback due to the regulatory issues with the Theranos’ operations. For the time being, Walgreens has closed its only Theranos Wellness Center in California and is mulling over the decision to be taken regarding the rest 40 centers in Arizona.
The US health insurers and pharmacy benefit managers are hopeful that the launch of Merck & Co Inc's new hepatitis C pill will improve their influence in price negotiations with drugmakers.
On Thursday, the Food and Drug Administration approved Merck's Zepatier for treatment of patients suffering from the most common type of the liver-destroying virus, genotype 1, and the less common genotype 4.
The new drug’s list price is $54,600 for a 12-week regimen in comparison to $94,500 for Gilead Sciences Inc's Harvoni. AbbVie Inc’s multi-pill regimen, Viekira Pak, has a list price of around $83,000.
The biopharmaceutical company Zafgen has announced the successful completion of the phase 3 trial of its treatment for an unusual genetic obesity disorder, known as Prader-Willi syndrome. The success comes after the trial of the treatment previously resulted in two deaths.
The Boston-based company’s beloranib has shown effectiveness in reducing weight of people suffering from this syndrome, which results in critical obesity due to intolerable hunger.
In a statement released yesterday evening at the World Economic Forum in Davos, about 100 pharmaceutical companies and trade associations said that governments should help solve the issue of no new antibiotics by funding and creating incentives for new drugs development.
They said that the value given to antibiotics and diagnostics generally doesn’t reflect the advantages they bring to society, nor the investment needed for their creation. They added, “We call on governments to commit to allocating the funds needed to create a sustainable and predictable market for these technologies while also implementing the measures needed to safeguard the effectiveness of antibiotics”.
Federal judge grants two-week restraining order against Arkansas law restricting use of abortion pillSubmitted by Deep Singh Bhangu on Fri, 01/01/2016 - 13:58
On Thursday, a federal judge granted a two-week restraining order against an Arkansas law, which restricts use of the so-called abortion pill. The grant has been given a day before the statute was to become effective.
The law has been challenged by Planned Parenthood of the Heartland, which has two clinics in Arkansas. On Wednesday, the US District Judge Kristine Baker heard arguments prior to permitting the group's request for a temporary stay that prevents the enforcement of the law, on Thursday.
Further arguments will be heard by the judge, but she said in her ruling that Planned Parenthood had a significant chance of prevailing in its argument that the statute is an unconstitutional violation of the right of a woman get an abortion done.
The world may have a dengue vaccine soon as Sanofi Pasteur has received approval from the Mexican government to market the first ever dengue vaccine that can prevent the fastest growing mosquito-borne disease in the world today.
In a press release, Swiftwater vaccine maker Sanofi informed that its tetravalent dengue vaccine Dengvaxia is capable of helping patients with the mosquito-borne disease caused by all four dengue virus types. “In two studies, the vaccine reduced dengue from all four viral variations in two-thirds of the participants. It also showed that the vaccine prevented 9 out of 10 cases of severe dengue and 8 out 10 hospitalizations due to dengue in this age group”, as per the company.
On Wednesday, officials said the Texas health department is going to cut off federal funding to a Houston Planned Parenthood affiliate for an about 30 years old HIV prevention program.
Texas Department of State Health Services spokesman Chris Van Deusen said that they have the discretion to expand the contract without elaborating anything and have elected not to do so. Deusen said that the area’s local health departments will provide the services there.
The Centers for Disease Control and Prevention federally funds the contract but it is managed by the state.
State officials sent a letter to Planned Parenthood Gulf Coast on Monday, saying that the $600,000 annual grant that will expire on December 31 is going to cut off indefinitely.
Texas health officials recently released a statement saying that the department has cut federal funding to a Houston affiliate of Planned Parenthood for a nearly three-decade-old HIV prevention program.
Republican leaders have been making several efforts to cut funding for Planned Parenthood after an anti-abortion group released videos showing officials of the reproductive health agency negotiating prices for fetal tissues from abortions it performs.
In response to the videos, Planned Parenthood said that the videos were heavily edited. The group denied admitting that it generated any profit from fetal tissue donation.
The inspector general’s office of the Department of Health and Human Services (HHS) has launched a review of how federal officials oversee fetal tissue research.
According to a report in the Wall Street Journal, Theranos, a beleaguered, multi-billion-dollar startup developing blood testing technology, is presently facing investigation by two federal agencies.
Former employees’ complaints have sparked the two investigations. One investigation is by the Food and Drug Administration, and the Centers for Medicare and Medicaid Services (CMS) is conducting the other one. As per the WSJ, the complaints gave rise to concerns over breached research protocols and severe accuracy issues with the company’s blood tests.
US health regulators are carrying out investigation into the complaints filed against laboratory and research practices at Theranos Inc. The complaints were filed by the former employees of the blood-testing startup company.
The first complaint was filed in September by a former Theranos lab employee to the Centers for Medicare and Medicaid Services. As per the complaint, the management instructed the lab employees to keep testing patients with the company’s blood-analysis devices despite knowing that the devices had some major stability, precision and accuracy problems.
Kaiser Permanente On Thursday announced that it is planning to open a medical school in Southern California by almost 2019. The company also said that it will be making more recruitments of minority students and teach doctors.
According to the company, achieving the goals of recruiting more minority students and teaching doctors has been a dream of medical schools throughout the country since long.
According to the Assn. of American Medical Colleges, several ethnic groups in medical schools are under-represented. This raises concerns that doctors might struggle to treat some minority groups like Latinos that make about 17% of the US population but only 9% of medical students.
On Wednesday, drug developer Advaxis Inc said that the US Food and Drug Administration had lifted a clinical ban on its three experimental cancer therapies. The move has sent the shares of the company up by as much as 38%.
In October, the US health regulator had put the mid-stage trials of the lead therapy of the company, axalimogene filolisbac, on hold following the death of a patient.
Then, Advaxis said that the patient has died because of progression of cervical cancer and no role was played by the drug in life loss. Later, the FDA put a clinical hold on all three therapies in the drug developer's pipeline.